The Medical Letter® On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769

The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited.

For further information call: 800-211-2769

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 54 (Issue 1384) February 20, 2012 www.medicalletter.org

IN BRIEF

5-HTP for Depression

A Medical Letter reader asked about the use of the nutritional supplement 5-hydroxytryptophan (5-HTP) for treatment of depression. It is sold in health food stores, pharmacies and on-line for many indications including depression, mood enhancement, emotional well being, and promotion of normal sleep.

5-HTP is the intermediate metabolite in the biosynthesis of serotonin from L-tryptophan. Many small studies in the 1970's and 1980's found 5-HTP helpful in the treatment of depression, but a Cochrane Review of 108 studies in patients with depression or dysthymia using 5-HTP or L-tryptophan found that the quality of the data was insufficient to establish the efficacy or safety of these products.

In 1989, contaminated L-tryptophan supplements were implicated as the causative agent in an outbreak of eosinophilia-myalgia syndrome (EMS), which was associated with some deaths. There is no evidence that 5-HTP could cause the syndrome.

There is no acceptable evidence that 5-HTP or L-tryptophan offers any advantage over a selective-serotonin reuptake inhibitor (SSRI) for treatment of depression. Taking 5-HTP or L-tryptophan in addition to an SSRI could cause serotonin syndrome.

There is no good reason to take 5-HTP or L-tryptophan.

- N Iovieno et al. Second-tier natural antidepressants: review and critique. J Affect Disord 2010; 130:343.
- K Shaw et al. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002; (1): CD003198.

The Medical Letter®

On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D.

EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School

EDITOR: Jean-Marie Pflomm, Pharm.D.

ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D., Corinne E. Zanone, Pharm.D.

CONSULTING EDITORS: Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D. CONTRIBUTING EDITORS:

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School

Eric J. Epstein, M.D., Albert Einstein College of Medicine

Jules Hirsch, M.D., Rockefeller University

David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre

Richard B. Kim, M.D., University of Western Ontario Hans Meinertz, M.D., University Hospital, Copenhagen

Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine

Dan M. Roden, M.D., Vanderbilt University School of Medicine

F. Estelle R. Simons, M.D., University of Manitoba

Jordan W. Smoller, M.D., Sc.D., Harvard Medical School

Neal H. Steigbigel, M.D., New York University School of Medicine

Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University

SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard

ASSOCIATE EDITOR: Cynthia Macapagal Covey

EDITORIAL FELLOW: Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School

MANAGING EDITOR: Susie Wong ASSISTANT MANAGING EDITOR: Liz Donohue PRODUCTION COORDINATOR: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona
FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski
DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino
VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address:

The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle. NY 10801-7537

Customer Service:

Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733

Fax: 914-632-1733 Web Site: www.medicalletter.org

E-mail: custserv@medicalletter.org **Permissions:**

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$98; 2 years - \$189; 3 years - \$279. \$49.00 per year for students, interns, residents and fellows in the US and Canada.

E-mail site license inquiries to:

info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.

Copyright 2012. ISSN 1523-2859







